Hasenin Al-Khersan, MD
Ophthalmology · Bellaire, TXNPI 1245761972
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,678 of the $75,864 with a category attached, or 66.8%. 22 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 24.4% of the total. 2025 is the largest year on record at $46,877, more than ten times the $686 reported in 2019. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $423.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$19K
- Ocular Therapeutix, Inc.$17K
- AbbVie$11K
- ANI Pharmaceuticals, Inc.$10K
- Genentech USA, Inc.$5K
- Regeneron$4K
- plus $10K from 16 others
Across 884 payments — averaging $2114.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.4M
- Boehringer Ingelheim$264K
- Ocular Therapeutix, Inc.$212K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$50,67867%
- Speaking & faculty fees$12,86517%
- Travel & lodging$3,5545%
- Food & beverage$8,76712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 22 | $18,545 |
| Ocular Therapeutix, Inc. | 20 | $16,690 |
| AbbVie(2 entities) | 23 | $11,241 |
| ANI Pharmaceuticals, Inc. | 2 | $10,255 |
| Genentech USA, Inc. | 18 | $5,210 |
| Regeneron | 9 | $4,073 |
| Alimera Sciences, Inc. | 11 | $2,573 |
| Regeneron Healthcare Solutions, Inc. | 30 | $1,918 |
| Dutch Ophthalmic, USA | 6 | $1,873 |
| Eyepoint US, Inc. | 5 | $1,210 |
| Alcon | 12 | $956 |
| Astellas Pharma US Inc | 8 | $247 |
| Mallinckrodt Enterprises LLC | 2 | $227 |
| Genentech, Inc. | 1 | $176 |
| Biotissue Holdings Inc. | 3 | $152 |
| Sight Sciences, Inc. | 1 | $123 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $120 |
| Rayner Intraocular Lenses Limited | 1 | $120 |
| Oculus Surgical Inc. | 1 | $57 |
| Topcon Healthcare, Inc. | 1 | $55 |
| Biogen | 1 | $26 |
| Neurotech Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$17,974
- PURIFIED CORTROPHIN GEL$10,125
- EYLEA HD$4,814
- YUTIQ$2,783
- VABYSMO$2,655
- Iluvien$2,360
- SUSVIMO$2,226
- EVA, combined machine$1,763
- TISSUEBLUE$1,115
- EYLEA$472
- Constellation$403
- DEXTENZA$349
- ACTHAR$227
- OMNI(R) SURGICAL SYSTEM (US)$123
- OZURDEX$123
- Tecnis Simplicity$120
- AcrySof IQ VIVITY IOL$112
- XEN GLAUCOMA TREATMENT SYSTEM$100
How this compares
$75,864 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 93 | $5,180 |
| MoxifloxacinMoxifloxacin Hcl | 46 | $948 |
| Ketorolac Tromethamine | 31 | $440 |
| Atropine Sulfate | 14 | $430 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $327 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $170 |
| Brimonidine Tartrate | 15 | $41 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bellaire
- Charles WykoffBellaire$1.5M
- Otis WaltonBellaire$311K
- Richard YeeBellaire$195K
- Prethy RaoBellaire$85K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.